Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?-Reference-Cited by-同舟云学术

Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?

Published:2022-02 Issue:2 Volume:164 Page:406-414
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Moya-Alarcón Carlota,González-Domínguez Almudena,Ivanova-Markova Yoana,Gimeno-Ballester Vicente,Barretina-Ginesta Maria-Pilar,Pérez-Fidalgo José Alejandro,Redondo Andrés

Funder

Eisai

GlaxoSmithKline

Roche

Amgen

AstraZeneca

Meso Scale Diagnostics

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference43 articles.

1. Las cifras del cáncer en España;Sociedad Española de Oncología Médica (SEOM),2021

2. Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2);Matz;Gynecol. Oncol.,2017

3. Minireview: human ovarian Cancer: biology, current management, and paths to personalizing therapy;Romero;Endocrinology.,2012

4. The SEOM hereditary Cancer working group, SEOM clinical guidelines in hereditary breast and ovarian cancer (2019);González-Santiago;Clin. Transl. Oncol.,2020

5. Integrated genomic analyses of ovarian carcinoma;The Cancer Genome Atlas Research Network;Nature.,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy;International Journal of Gynecologic Cancer;2023-12-02

2. Cost-effectiveness of PARP inhibitors in malignancies: A systematic review;PLOS ONE;2022-12-15

3. Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis;Journal of Obstetrics and Gynaecology;2022-12-09

4. Olaparib cost effective for in BRCA-mutated advanced ovarian carcinoma in Spain;PharmacoEconomics & Outcomes News;2021-12